ICU Medical (NASDAQ:ICUI) has been given a consensus rating of “Buy” by the six analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $266.00.
Several equities analysts have recently issued reports on ICUI shares. BidaskClub raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 7th. Zacks Investment Research raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $266.00 price target for the company in a research note on Tuesday, January 23rd.
NASDAQ:ICUI traded down $0.75 on Tuesday, hitting $255.85. The company had a trading volume of 63,639 shares, compared to its average volume of 205,680. The company has a market cap of $5,205.60, a price-to-earnings ratio of 46.35, a PEG ratio of 2.58 and a beta of 0.36. ICU Medical has a 52 week low of $144.25 and a 52 week high of $265.27.
ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, March 1st. The medical instruments supplier reported $2.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $1.94. The firm had revenue of $370.12 million during the quarter, compared to the consensus estimate of $332.91 million. ICU Medical had a net margin of 5.31% and a return on equity of 8.42%. The company’s revenue for the quarter was up 286.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.20 earnings per share. equities analysts predict that ICU Medical will post 6.29 earnings per share for the current fiscal year.
In other ICU Medical news, Director Robert S. Swinney sold 724 shares of the firm’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $235.00, for a total value of $170,140.00. Following the completion of the sale, the director now directly owns 14,830 shares in the company, valued at $3,485,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director George A. Lopez sold 26,475 shares of the firm’s stock in a transaction on Wednesday, April 4th. The stock was sold at an average price of $246.73, for a total transaction of $6,532,176.75. Following the completion of the sale, the director now owns 494,025 shares of the company’s stock, valued at $121,890,788.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,176 shares of company stock valued at $13,945,286. 13.60% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the business. Exane Derivatives acquired a new stake in ICU Medical in the fourth quarter worth $100,000. Israel Discount Bank of New York grew its holdings in ICU Medical by 74.8% in the fourth quarter. Israel Discount Bank of New York now owns 853 shares of the medical instruments supplier’s stock worth $184,000 after purchasing an additional 365 shares during the period. First Republic Investment Management Inc. acquired a new stake in ICU Medical in the fourth quarter worth $200,000. Raymond James Trust N.A. acquired a new stake in ICU Medical in the fourth quarter worth $204,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in ICU Medical by 39.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 984 shares of the medical instruments supplier’s stock worth $213,000 after purchasing an additional 277 shares during the period. Institutional investors and hedge funds own 76.92% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “ICU Medical (ICUI) Receives Consensus Recommendation of “Buy” from Brokerages” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/15/icu-medical-icui-receives-consensus-recommendation-of-buy-from-brokerages.html.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein for use in hospitals and ambulatory clinics.
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.